Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative disease characterized by behavioral abnormalities, personality changes, language dysfunction, and can co-occur with the development of motor neuron disease. One major pathological form of FTLD is characterized by intracellular deposition of ubiquitinated and phosphorylated TAR DNA binding protein-43 (TDP-43), suggesting that dysregulation in phosphorylation events may contribute to disease progression. However, to date systematic analysis of the phosphoproteome in FTLD brains has not been reported. In this study, we employed immobilized metal affinity chromatography (IMAC) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify phosphopeptides from FTLD and age-matched control post-mortem human brain tissue. Using this approach, we identified 786 phosphopeptides in frontal cortex (control and FTLD), in which the population of phosphopeptides represented approximately 50% of the total peptides analyzed. Label-free quantification using spectral counts revealed six proteins with significant changes in the FTLD phosphoproteome. N-myc-Downstream regulated gene 2 (NDRG2) and glial fibrillary acidic protein (GFAP) had an increased number of phosphospectra in FTLD, whereas microtubule associated protein 1A (MAP1A), reticulon 4 (RTN4; also referred to as neurite outgrowth inhibitor (Nogo)), protein kinase C gamma (PRKCG), and heat shock protein 90 kDa alpha, class A member 1(HSP90AA1) had significantly fewer phosphospectra compared to control brain. To validate these differences, we examined NDRG2 phosphorylation in FTLD brain by immunoblot analyses, and using a phosphoserine-13 (pSer13) GFAP monoclonal antibody we show an increase in pSer13 GFAP levels by immunoblot concomitant with increased overall GFAP levels in FTLD cases. These data highlight the utility of combining proteomic and phosphoproteomic strategies to characterize post-mortem human brain tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Mackenzie, I. R. A., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., Kwong, L. K., Forman, M. S., Ravits, J., Stewart, H., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21147 · Cited by 992
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715 · cited 1×
“Briefly, the G-value of each protein was calculated as shown in equation (1):”
MethodKislinger, T., Cox, B., Kannan, A., Chung, C., Hu, P., Ignatchenko, A., Scott, M. S., Gramolini, A. O., Morris, Q., Hallett, M. T., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.044 · Cited by 482
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Cited by
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I.-S., Duong, D. M., Seyfried, N. T., Hu, W. T., Liu, Z., Wang, J.-Z., et al. (2014) · Nature Medicine · doi:10.1038/nm.3700 · Cited by 494
Self-citationROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Enteric GFAP expression and phosphorylation in Parkinson's disease
Clairembault, T., Kamphuis, W., Leclair‐Visonneau, L., Rolli‐Derkinderen, M., Coron, E., Neunlist, M., Hol, E. M., & Derkinderen, P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12742 · Cited by 191
Herskowitz, J. H., Feng, Y., Mattheyses, A. L., Hales, C. M., Higginbotham, L. A., Duong, D. M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Seyfried, N. T., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2508-13.2013 · Cited by 150
“Immunohistochemical staining procedures were performed as previously described (Herskowitz et al., 2010).”
MethodSelf-citationEnteric glial cells: New players in Parkinson's disease?
Clairembault, T., Leclair‐Visonneau, L., Neunlist, M., & Derkinderen, P. (2015) · Movement Disorders · doi:10.1002/mds.25979 · Cited by 117
Neuron Enriched Nuclear Proteome Isolated from Human Brain
Dammer, E. B., Duong, D. M., Diner, I., Gearing, M., Feng, Y., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2013) · Journal of Proteome Research · doi:10.1021/pr400246t · Cited by 70
Self-citationSeyfried, N. T., Gozal, Y. M., Donovan, L. E., Herskowitz, J. H., Dammer, E. B., Xia, Q., Ku, L., Chang, J., Duong, D. M., Rees, H. D., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr2010814 · Cited by 64
“Label-free spectral counting was used to determine differences between the control (CTL) and FTLD detergent-insoluble proteomes using SC and G-test as previously described [34, 35].”
MethodSelf-citationAggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease
Diner, I., Hales, C. M., Bishof, I., Rabenold, L., Duong, D. M., Yi, H., Laur, O., Gearing, M., Troncoso, J., Thambisetty, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562959 · Cited by 63
“A user defined peptide precursor mass tolerance of 20 ppm was employed for extracted ion chromatogram (XIC) based quantification (32).”
MethodSelf-citationSchonkeren, S. L., Massen, M., van der Horst, R., Koch, A., Vaes, N., & Melotte, V. (2019) · neurogenetics · doi:10.1007/s10048-019-00587-0 · Cited by 57
Hu, Y., Ren, R., Zhang, Y., Huang, Y., Cui, H., Ma, C., Qiu, W., Wang, H., Cui, P., Chen, H., et al. (2019) · Aging Cell · doi:10.1111/acel.13001 · Cited by 33
“…μM, Abcam), 1 × NEB PK buffer, and 200 μM ATP for 3 hr at 30°C. Samples were digested with trypsin, and the resulting peptides were analyzed by reverse‐ phase liquid chromatography coupled with tandem mass spectrome‐ try (LC‐MS/MS) independently as previously described (Herskowitz et al., 2010).”
Method
Metadata
- Authors
- Herskowitz, J. H., Seyfried, N. T., Duong, D. M., Xia, Q., Rees, H. D., Gearing, M., Peng, J., Lah, J. J., & Levey, A. I.
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-10-22
- Volume
- 9
- Issue
- 12
- Pages
- 6368-6379
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- OpenAlex
- W2087608585
- Cited by
- 75
- References
- 16
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.